Japan Cell and Gene Therapy Manufacturing Market: Industry Trends and Future Forecast, Till 2035 - Distribution by Type of Therapy, Type of Scale, Type of Mode, Type of Workflow, Type of Process, Type of Technology, End User and Leading Players

The Japan cell and gene therapy market is estimated to grow from USD 521 million in the current year to USD 5.15 billion by 2035 at a CAGR of 29.0% during the forecast period, till 2035.

Japan Cell and Gene Therapy Manufacturing Market: Growth and Trends

Innovative treatments, including cell and gene therapies, have shown incredible promise in addressing chronic illnesses, cancer-related conditions, and rare diseases. These therapies are intricately developed to precisely target diseases at the cellular level and minimize the risk of off-target effects. Cell and gene therapy provide various benefits, including targeted responses, restoration of damaged tissues, halting or slowing inherited diseases, and enabling the treatment of specific genes that are either defective or altered.

Japan's cell and gene therapy market is experiencing robust growth, fueled by regulatory support, an aging population, and rising chronic disease prevalence. Further, Japan's regulatory framework accelerates approvals for breakthrough therapies. An aging population boosts demand for treatments targeting cancer, genetic disorders, and cardiovascular diseases, while R&D investments from government and industry propel innovation. Owing to the abovementioned developments, the Japan cell and gene therapy market is poised for notable future growth, with projections showing sustained CAGRs during the forecast period.

Growth Drivers: Strategic Enablers of Market Expansion

The market drivers for cell and gene therapy manufacturing market in Japan include advancements in biotechnology like CRISPR and CAR-T therapies enabling precise, curative treatments for previously untreatable diseases, bolstered by personalized medicine trends. In addition, the aging population in Japan heightens demand for solutions targeting cancer, degenerative disorders, and rare genetic conditions, while government initiatives accelerate approvals and R&D investments. Further, strong industry-academia collaborations enhance iPS cell workflows and clinical translation of cell and gene therapies.

Market Challenges: Critical Barriers Impeding Progress

Despite the expanding clinical pipeline, the production of cell and gene therapies encounters numerous challenges. Elevated development and manufacturing costs, coupled with complex scalability for autologous therapies, limit accessibility despite regulatory speed. Reimbursement hurdles persist for high-price therapies amid Japan's universal healthcare system, alongside needs for skilled personnel and robust infrastructure. Stringent safety requirements under Pharmaceuticals and Medical Devices Agency (PMDA) and global standardization gaps slow international pipeline adoption.

Cell Therapies: Leading Market Segment

Our estimates suggest that the production of cell therapies represents the largest market share. This dominance stems from an increasing focus on developing cell-based therapies such as CAR-T cell therapy to tackle different diseases, especially cancer. Consequently, the increasing demand for groundbreaking cell therapies is driving the most significant growth share of this sector. It is important to highlight that the gene therapies sector will demonstrate considerable growth potential and is expected to attain a greater CAGR during the forecast period. Gene therapies have shown significant results in curing and stopping disease progression, coupled with growing research on gene mutations and the evaluation of gene therapies for treating diseases

Pre-commercial / R&D Scale Manufacturing: Dominating Market Segment

Currently, the market is mainly driven by pre-commercial / R&D scale production, which accounts for almost 70% of the share. Various factors, such as an expanding pipeline of cell and gene therapies and increased investment in R&D for large-scale manufacturing, play a role in this share. It is anticipated that commercial-scale manufacturing will grow at the highest CAGR during the entire forecasting period. This is primarily due to the growing approval of cell and gene therapy products by the USFDA. With the increasing approval and accessibility of major viral vector and plasmid DNA production, a substantial rise in demand for commercial scale manufacturing is expected.

Japan Cell and Gene Therapy Manufacturing Market: Key Segments

Type of Therapy

• Cell Therapies (Stem Cell Therapy and Non-Stem Cell Therapy)
• Gene Therapies

Type of Scale

• Precommercial / R&D Scale Manufacturing
• Commercial Scale Manufacturing

Type of Mode

• Contract Manufacturing
• In-House Manufacturing

Type of Workflow

• C Cell Processing
• Cell Banking
• Process Development
• Fill & Finish Operations
• Analytical & Quality Testing
• Raw Material Testing
• Vector Production
• Other Workflow

Type of Process

• Upstream Processes
• Downstream Processes

Type of Technology

• Fluorescence-Activated Cell Sorting (FACS)
• Enzyme-Linked Immunosorbent Assay (ELISA)
• Chromatography
• Next-Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Other Technologies

End User

• Pharmaceutical Companies
• Biopharmaceutical / Biotechnological Companies
• Contract Manufacturing Organizations

Example Players in the Japan Cell and Gene Therapy Market

• AGC
• Astellas Pharma
• Catalent
• Charles River Laboratories
• Cytiva
• Fujifilm Cellular Dynamics
• OmniAb
• Rentschler Biopharma
• Takeda Pharmaceutical
• Thermo Fisher Scientific
• Wuxi AppTec

Key Questions Answered in this Report

• How many Japan cell and gene therapy manufacturers are currently engaged in this market?
• Which are the leading companies in this market?
• Which country dominates the Japan cell and gene therapy market?
• What are the key trends observed in the Japan cell and gene therapy market?
• What factors are likely to influence the evolution of this market?
• What are the primary challenges faced by Japan cell and gene therapy manufacturers?
• What is the current and future Japan cell and gene therapy market size?
• What is the CAGR of Japan cell and gene therapy market?
• How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
• The report can aid businesses in identifying future opportunities in any sector. It also helps in understanding if those opportunities are worth pursuing.
• The report helps in identifying customer demand by understanding the needs, preferences, and behavior of the target audience in order to tailor products or services effectively.
• The report equips new entrants with requisite information regarding a particular market to help them build successful business strategies.
• The report allows for more effective communication with the audience and in building strong business relations.

Complementary Benefits

• Complimentary Excel Data Packs Covering All Analytical Modules
• Up to 15% Complimentary Content Customization
• In-Depth Report Walkthrough with the Research Team
• Complimentary Report Update if the Report is 6+ Months Old